|
|
|
ANGIOTENSIN II SIGNALING PATHWAY (PW:0000244)
DescriptionAgiotensin II (AgtII), the product of Ace action in the renin-angiotensin system, is probably the most potent of the biologically active peptides the pathway generates. The system, originally viewed as solely endocrine, is now regarded as an endocrine, paracrine and autocrine one, producing an array of diverse and many times opposing actions via both the 'classical' or circulatory and the local or 'tissue' routes. Overall AgtII elicits distinct responses through signaling via receptor type 1 and 2, Agtr1 and Agtr2, respectively. Of the two receptors, Agtr1 which is expressed in most tissues and which in rodents is represented by two genes that are 95% identical in their amino acid sequences, is the better understood system. The Agtr1 mediated pathway is involved in vasoconstriction, proliferation, hormone release and fluid homeostasis. Activated Agtr1 couples to members of the Galphaq family of heterotrimeric G proteins whose signal transduction leads to activation of phopholipase C followed by activation of protein kinase C signaling pathway and the events downstream of it. In response to AgtII, Agtr1 can also mediate G protein independent signaling. In addition, Agtr1 may be active in the absence of ligand binding. The powerful but potentially harmful effects elicited by Agtr1 are counterbalanced by the Agtr2 mediated signaling. This pathway promotes vasodilation, NO release and growth inhibition. Agtr2, initially believed not to engage heterotrimeric G proteins was later shown to couple to members of the Galphai family. Agtr2 activates several protein phosphatases in a G protein dependent and independent manner resulting in inactivation of MAPK cascades thus conducive to antiproliferative effects. Agtr2 also prompts release of nitric oxide (NO) and increase in intracellular cGMP levels in a manner that is both dependent and independent of bradykinin receptor 2 (B2) and leading to vasodilator effects. Like in the case of Agtr1, Agtr2 mediated signaling can be G protein as well as ligand independent. However, the molecular mechanisms of Agtr2 mediated signaling are not well understood and the currently available information, at times is thought of as being controversial. Agtr1 and Agtr2 can form homodimers as well as heterodimers with other GPCRs and with one another. Deregulation of AgtII signaling has been implicated in cardiovascular and renal disorders. ...(less)
|
Pathway Diagram:
|
|
|
Genes in Pathway:
angiotensin II signaling pathway
|
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
|
ISS |
10 |
95,361,338 |
95,381,455 |
RGD:1581742 |
RGD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
|
TAS |
19 |
54,738,556 |
54,750,349 |
RGD:1581847 |
RGD |
| G |
Agtr1a |
angiotensin II receptor, type 1a |
|
|
TAS |
17 |
40,629,318 |
40,684,982 |
RGD:1579760 |
RGD |
| G |
Agtr1b |
angiotensin II receptor, type 1b |
|
|
TAS |
2 |
105,503,269 |
105,602,591 |
RGD:629553 |
RGD |
| G |
Agtr2 |
angiotensin II receptor, type 2 |
|
|
TAS |
|
|
|
RGD:1566502 |
RGD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
|
IEP |
10 |
70,256,263 |
70,258,061 |
RGD:1582323 |
RGD |
| G |
Cma1 |
chymase 1, mast cell |
|
|
IMP |
15 |
34,083,202 |
34,084,387 |
RGD:1581745 |
RGD |
| G |
Jak2 |
Janus kinase 2 |
|
|
IMP |
1 |
232,915,995 |
232,974,763 |
RGD:1600094 |
RGD |
| G |
Nrg1 |
neuregulin 1 |
|
|
IEP |
16 |
63,937,796 |
64,126,183 |
RGD:1581606 |
RGD |
| G |
Olr1 |
oxidized low density lipoprotein (lectin-like) receptor 1 |
|
|
IEP |
4 |
166,747,228 |
166,769,340 |
RGD:1580992 |
RGD |
| G |
Pdpk1 |
3-phosphoinositide dependent protein kinase-1 |
|
|
IDA |
10 |
13,329,708 |
13,394,080 |
RGD:1581775 |
RGD |
| G |
Prkcz |
protein kinase C, zeta |
|
|
IMP |
5 |
172,061,825 |
172,172,793 |
RGD:1642674 |
RGD |
angiotensin II signaling pathway via AT1 receptor
|
| G |
Adrbk1 |
adrenergic, beta, receptor kinase 1 |
|
|
ISS |
1 |
206,873,002 |
206,892,868 |
RGD:5133417 |
RGD |
| G |
Adrbk2 |
adrenergic, beta, receptor kinase 2 |
|
|
ISS |
|
|
|
RGD:5133417 |
RGD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
|
TAS |
19 |
54,738,556 |
54,750,349 |
RGD:1581847 |
RGD |
| G |
Agtr1a |
angiotensin II receptor, type 1a |
|
|
TAS |
17 |
40,629,318 |
40,684,982 |
RGD:1581825 |
RGD |
| G |
Agtr1a |
angiotensin II receptor, type 1a |
|
|
IDA |
17 |
40,629,318 |
40,684,982 |
RGD:5133683 |
RGD |
| G |
Agtr1a |
angiotensin II receptor, type 1a |
|
|
IDA |
17 |
40,629,318 |
40,684,982 |
RGD:2316188 |
RGD |
| G |
Agtr1b |
angiotensin II receptor, type 1b |
|
|
TAS |
2 |
105,503,269 |
105,602,591 |
RGD:1581825 |
RGD |
| G |
Agtrap |
angiotensin II receptor-associated protein |
|
|
IMP |
5 |
165,154,252 |
165,164,570 |
RGD:2314353 |
RGD |
| G |
Arap1 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 |
|
|
IDA |
1 |
158,872,249 |
158,912,164 |
RGD:2316188 |
RGD |
| G |
Arrb1 |
arrestin, beta 1 |
|
|
ISS |
1 |
156,871,564 |
156,937,540 |
RGD:5133417 |
RGD |
| G |
Arrb2 |
arrestin, beta 2 |
|
|
ISS |
10 |
57,244,071 |
57,284,166 |
RGD:5133417 |
RGD |
| G |
Gna11 |
guanine nucleotide binding protein, alpha 11 |
|
|
ISS |
7 |
9,636,748 |
9,662,492 |
RGD:1581847 |
RGD |
| G |
Gnaq |
guanine nucleotide binding protein (G protein), q polypeptide |
|
|
ISS |
1 |
219,520,998 |
219,764,401 |
RGD:1581847 |
RGD |
| G |
Grk5 |
G protein-coupled receptor kinase 5 |
|
|
ISS |
1 |
267,495,534 |
267,693,144 |
RGD:5133417 |
RGD |
| G |
Grk6 |
G protein-coupled receptor kinase 6 |
|
|
ISS |
17 |
15,220,992 |
15,236,617 |
RGD:5133417 |
RGD |
| G |
Jak2 |
Janus kinase 2 |
|
|
IMP |
1 |
232,915,995 |
232,974,763 |
RGD:6478796 |
RGD |
| G |
Jak2 |
Janus kinase 2 |
|
|
IDA |
1 |
232,915,995 |
232,974,763 |
RGD:5133683 |
RGD |
| G |
Rgs2 |
regulator of G-protein signaling 2 |
|
|
ISS |
13 |
57,891,849 |
57,894,452 |
RGD:5133418 |
RGD |
| G |
Tyk2 |
tyrosine kinase 2 |
|
|
IMP |
8 |
20,096,969 |
20,149,004 |
RGD:6478796 |
RGD |
angiotensin II signaling pathway via AT2 receptor
|
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
|
TAS |
19 |
54,738,556 |
54,750,349 |
RGD:1582435 |
RGD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
|
IMP |
19 |
54,738,556 |
54,750,349 |
RGD:1582434 |
RGD |
| G |
Agtr2 |
angiotensin II receptor, type 2 |
|
|
TAS |
|
|
|
RGD:1581825 |
RGD |
G protein mediated signaling pathway via Galpha12/Galpha13 family
|
| G |
Agtr1a |
angiotensin II receptor, type 1a |
|
|
IMP |
17 |
40,629,318 |
40,684,982 |
RGD:1582440 |
RGD |
| G |
Gna13 |
guanine nucleotide binding protein (G protein), alpha 13 |
|
|
IMP |
10 |
98,933,205 |
98,965,819 |
RGD:1582440 |
RGD |
| G |
Gnb1 |
guanine nucleotide binding protein (G protein), beta polypeptide 1 |
|
|
IMP |
5 |
172,341,135 |
172,386,772 |
RGD:1582440 |
RGD |
| G |
Gng3 |
guanine nucleotide binding protein (G protein), gamma 3 |
|
|
IMP |
1 |
211,507,640 |
211,509,406 |
RGD:1582440 |
RGD |
| G |
Rgs12 |
regulator of G-protein signaling 12 |
|
|
ISS |
14 |
81,363,542 |
81,436,194 |
RGD:7207227 |
RGD |
G protein mediated signaling pathway via Galphai family
|
| G |
Adrb2 |
adrenoceptor beta 2, surface |
|
|
IMP |
18 |
58,174,958 |
58,177,000 |
RGD:1559319 |
RGD |
| G |
Agtr2 |
angiotensin II receptor, type 2 |
|
|
TAS |
|
|
|
RGD:1566502 |
RGD |
| G |
Casr |
calcium-sensing receptor |
|
|
IMP |
11 |
66,084,169 |
66,153,292 |
RGD:7207059 |
RGD |
| G |
Drd2 |
dopamine receptor D2 |
|
|
ISS |
8 |
52,641,160 |
52,707,749 |
RGD:1581445 |
RGD |
| G |
Gnai1 |
guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 |
|
|
IMP |
4 |
12,465,089 |
12,495,028 |
RGD:1642020 |
RGD |
| G |
Hcrtr2 |
hypocretin (orexin) receptor 2 |
|
|
IDA |
8 |
81,068,303 |
81,196,608 |
RGD:1642020 |
RGD |
| G |
Lpar1 |
lysophosphatidic acid receptor 1 |
|
|
IMP |
5 |
76,449,470 |
76,571,458 |
RGD:1626474 |
RGD |
| G |
Lpar3 |
lysophosphatidic acid receptor 3 |
|
|
IMP |
2 |
244,431,789 |
244,510,815 |
RGD:1626474 |
RGD |
| G |
Oxtr |
oxytocin receptor |
|
|
ISS |
4 |
148,314,089 |
148,326,797 |
RGD:1579893 |
RGD |
| G |
Oxtr |
oxytocin receptor |
|
|
IMP |
4 |
148,314,089 |
148,326,797 |
RGD:2304227 |
RGD |
| G |
Rgs4 |
regulator of G-protein signaling 4 |
|
|
ISS |
13 |
85,533,882 |
85,540,173 |
RGD:7207227 |
RGD |
| G |
Rgs5 |
regulator of G-protein signaling 5 |
|
|
ISS |
13 |
85,445,325 |
85,482,294 |
RGD:7207228 |
RGD |
| G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
|
|
IMP |
2 |
211,851,304 |
211,855,511 |
RGD:1581747 |
RGD |
G protein mediated signaling pathway via Galphaq family
|
| G |
Adra1a |
adrenoceptor alpha 1A |
|
|
ISS |
15 |
46,173,429 |
46,263,198 |
RGD:1559318 |
RGD |
| G |
Adra1b |
adrenoceptor alpha 1B |
|
|
ISS |
10 |
28,889,092 |
28,946,889 |
RGD:1559318 |
RGD |
| G |
Adra1d |
adrenoceptor alpha 1D |
|
|
ISS |
3 |
119,279,974 |
119,295,985 |
RGD:1559318 |
RGD |
| G |
Agtr1a |
angiotensin II receptor, type 1a |
|
|
IMP |
17 |
40,629,318 |
40,684,982 |
RGD:70819 |
RGD |
| G |
Agtr1a |
angiotensin II receptor, type 1a |
|
|
TAS |
17 |
40,629,318 |
40,684,982 |
RGD:629553 |
RGD |
| G |
Agtr1b |
angiotensin II receptor, type 1b |
|
|
TAS |
2 |
105,503,269 |
105,602,591 |
RGD:629553 |
RGD |
| G |
Avpr1a |
arginine vasopressin receptor 1A |
|
|
ISS |
7 |
62,225,537 |
62,229,461 |
RGD:1579891 |
RGD |
| G |
Avpr1b |
arginine vasopressin receptor 1B |
|
|
ISS |
13 |
44,537,103 |
44,547,318 |
RGD:1579891 |
RGD |
| G |
Avpr1b |
arginine vasopressin receptor 1B |
|
|
IDA |
13 |
44,537,103 |
44,547,318 |
RGD:2312649 |
RGD |
| G |
Casr |
calcium-sensing receptor |
|
|
IMP |
11 |
66,084,169 |
66,153,292 |
RGD:7207227 |
RGD |
| G |
Casr |
calcium-sensing receptor |
|
|
IMP |
11 |
66,084,169 |
66,153,292 |
RGD:7207059 |
RGD |
| G |
Ghsr |
growth hormone secretagogue receptor |
|
|
TAS |
2 |
113,269,623 |
113,272,999 |
RGD:1642818 |
RGD |
| G |
Gna11 |
guanine nucleotide binding protein, alpha 11 |
|
|
ISS |
7 |
9,636,748 |
9,662,492 |
RGD:1579891 |
RGD |
| G |
Gna11 |
guanine nucleotide binding protein, alpha 11 |
|
|
ISS |
7 |
9,636,748 |
9,662,492 |
RGD:5131495 |
RGD |
| G |
Gna14 |
guanine nucleotide binding protein, alpha 14 |
|
|
ISS |
1 |
219,906,120 |
219,983,252 |
RGD:5131495 |
RGD |
| G |
Gna15 |
guanine nucleotide binding protein, alpha 15 |
|
|
IMP |
7 |
9,669,956 |
9,689,442 |
RGD:728647 |
RGD |
| G |
Gna15 |
guanine nucleotide binding protein, alpha 15 |
|
|
ISS |
7 |
9,669,956 |
9,689,442 |
RGD:5131495 |
RGD |
| G |
Gnaq |
guanine nucleotide binding protein (G protein), q polypeptide |
|
|
IMP |
1 |
219,520,998 |
219,764,401 |
RGD:1642020 |
RGD |
| G |
Gnaq |
guanine nucleotide binding protein (G protein), q polypeptide |
|
|
ISS |
1 |
219,520,998 |
219,764,401 |
RGD:1579891 |
RGD |
| G |
Gnaq |
guanine nucleotide binding protein (G protein), q polypeptide |
|
|
ISS |
1 |
219,520,998 |
219,764,401 |
RGD:5131495 |
RGD |
| G |
Hcrtr1 |
hypocretin (orexin) receptor 1 |
|
|
IDA |
5 |
149,160,739 |
149,170,736 |
RGD:1642020 |
RGD |
| G |
Hcrtr2 |
hypocretin (orexin) receptor 2 |
|
|
IDA |
8 |
81,068,303 |
81,196,608 |
RGD:1642020 |
RGD |
| G |
Lpar1 |
lysophosphatidic acid receptor 1 |
|
|
IMP |
5 |
76,449,470 |
76,571,458 |
RGD:1626471 |
RGD |
| G |
Lpar3 |
lysophosphatidic acid receptor 3 |
|
|
IMP |
2 |
244,431,789 |
244,510,815 |
RGD:1626471 |
RGD |
| G |
Oxtr |
oxytocin receptor |
|
|
ISS |
4 |
148,314,089 |
148,326,797 |
RGD:1579891 |
RGD |
| G |
Oxtr |
oxytocin receptor |
|
|
IMP |
4 |
148,314,089 |
148,326,797 |
RGD:2304227 |
RGD |
| G |
Plcb1 |
phospholipase C, beta 1 (phosphoinositide-specific) |
|
|
ISS |
3 |
122,797,718 |
123,523,675 |
RGD:5131495 |
RGD |
| G |
Plcb2 |
phospholipase C, beta 2 |
|
|
ISS |
3 |
105,203,524 |
105,223,342 |
RGD:5131495 |
RGD |
| G |
Plcb3 |
phospholipase C, beta 3 (phosphatidylinositol-specific) |
|
|
ISS |
1 |
209,628,425 |
209,643,694 |
RGD:5131495 |
RGD |
| G |
Plcb4 |
phospholipase C, beta 4 |
|
|
ISS |
3 |
123,706,313 |
124,077,381 |
RGD:5131495 |
RGD |
| G |
Pth1r |
parathyroid hormone 1 receptor |
|
|
IDA |
8 |
115,099,763 |
115,119,362 |
RGD:7207455 |
RGD |
| G |
Pth1r |
parathyroid hormone 1 receptor |
|
|
ISS |
8 |
115,099,763 |
115,119,362 |
RGD:7207465 |
RGD |
| G |
Pth1r |
parathyroid hormone 1 receptor |
|
|
ISS |
8 |
115,099,763 |
115,119,362 |
RGD:7207470 |
RGD |
| G |
Rgs2 |
regulator of G-protein signaling 2 |
|
|
ISS |
13 |
57,891,849 |
57,894,452 |
RGD:7207227 |
RGD |
| G |
Rgs2 |
regulator of G-protein signaling 2 |
|
|
ISS |
13 |
57,891,849 |
57,894,452 |
RGD:5133418 |
RGD |
| G |
Rgs4 |
regulator of G-protein signaling 4 |
|
|
ISS |
13 |
85,533,882 |
85,540,173 |
RGD:7207227 |
RGD |
| G |
Rgs5 |
regulator of G-protein signaling 5 |
|
|
ISS |
13 |
85,445,325 |
85,482,294 |
RGD:7207228 |
RGD |
G protein mediated signaling pathway via Galphas family
|
| G |
Adcy1 |
adenylate cyclase 1 (brain) |
|
|
ISS |
14 |
87,812,256 |
87,923,402 |
RGD:2312469 |
RGD |
| G |
Adcy2 |
adenylate cyclase 2 (brain) |
|
|
ISS |
17 |
4,543,466 |
5,040,433 |
RGD:2312469 |
RGD |
| G |
Adcy3 |
adenylate cyclase 3 |
|
|
ISS |
6 |
27,118,325 |
27,202,275 |
RGD:2312469 |
RGD |
| G |
Adcy4 |
adenylate cyclase 4 |
|
|
ISS |
15 |
33,930,531 |
33,946,352 |
RGD:2312469 |
RGD |
| G |
Adcy5 |
adenylate cyclase 5 |
|
|
ISS |
11 |
67,290,968 |
67,437,468 |
RGD:2312469 |
RGD |
| G |
Adcy5 |
adenylate cyclase 5 |
|
|
IDA |
11 |
67,290,968 |
67,437,468 |
RGD:2315004 |
RGD |
| G |
Adcy6 |
adenylate cyclase 6 |
|
|
IDA |
7 |
137,339,933 |
137,360,020 |
RGD:2313211 |
RGD |
| G |
Adcy6 |
adenylate cyclase 6 |
|
|
IDA |
7 |
137,339,933 |
137,360,020 |
RGD:2315004 |
RGD |
| G |
Adcy6 |
adenylate cyclase 6 |
|
|
ISS |
7 |
137,339,933 |
137,360,020 |
RGD:2312469 |
RGD |
| G |
Adcy7 |
adenylate cyclase 7 |
|
|
ISS |
19 |
20,051,639 |
20,073,861 |
RGD:2312469 |
RGD |
| G |
Adcy8 |
adenylate cyclase 8 (brain) |
|
|
ISS |
7 |
101,957,807 |
102,210,346 |
RGD:2312469 |
RGD |
| G |
Adcy9 |
adenylate cyclase 9 |
|
|
ISS |
|
|
|
RGD:2312469 |
RGD |
| G |
Adrb1 |
adrenoceptor beta 1 |
|
|
TAS |
1 |
263,025,655 |
263,027,055 |
RGD:1559319 |
RGD |
| G |
Adrb2 |
adrenoceptor beta 2, surface |
|
|
TAS |
18 |
58,174,958 |
58,177,000 |
RGD:1559319 |
RGD |
| G |
Adrb3 |
adrenoceptor beta 3 |
|
|
ISS |
16 |
69,163,620 |
69,166,384 |
RGD:1559323 |
RGD |
| G |
Adrbk1 |
adrenergic, beta, receptor kinase 1 |
|
|
TAS |
1 |
206,873,002 |
206,892,868 |
RGD:632163 |
RGD |
| G |
Adrbk2 |
adrenergic, beta, receptor kinase 2 |
|
|
TAS |
|
|
|
RGD:632163 |
RGD |
| G |
Avpr1b |
arginine vasopressin receptor 1B |
|
|
IDA |
13 |
44,537,103 |
44,547,318 |
RGD:2312649 |
RGD |
| G |
Avpr2 |
arginine vasopressin receptor 2 |
|
|
ISS |
X |
159,821,860 |
159,823,488 |
RGD:1579891 |
RGD |
| G |
Gcgr |
glucagon receptor |
|
|
IDA |
10 |
109,921,411 |
109,929,577 |
RGD:2315004 |
RGD |
| G |
Gnas |
GNAS complex locus |
|
|
IMP |
3 |
165,213,399 |
165,214,551 |
RGD:1625210 |
RGD |
| G |
Gnas |
GNAS complex locus |
|
|
IDA |
3 |
165,213,399 |
165,214,551 |
RGD:2313211 |
RGD |
| G |
Gnas |
GNAS complex locus |
|
|
IDA |
3 |
165,213,399 |
165,214,551 |
RGD:1580407 |
RGD |
| G |
Gnas |
GNAS complex locus |
|
|
IDA |
3 |
165,213,399 |
165,214,551 |
RGD:2315004 |
RGD |
| G |
Gnas |
GNAS complex locus |
|
|
ISS |
3 |
165,213,399 |
165,214,551 |
RGD:1579891 |
RGD |
| G |
Gnas |
GNAS complex locus |
|
|
ISS |
3 |
165,213,399 |
165,214,551 |
RGD:2312469 |
RGD |
| G |
Gper |
G protein-coupled estrogen receptor 1 |
|
|
ISS |
12 |
15,718,615 |
15,719,893 |
RGD:5128698 |
RGD |
| G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
|
|
IDA |
6 |
12,613,622 |
12,651,587 |
RGD:2292602 |
RGD |
| G |
Pth1r |
parathyroid hormone 1 receptor |
|
|
ISS |
8 |
115,099,763 |
115,119,362 |
RGD:7207465 |
RGD |
| G |
Pth1r |
parathyroid hormone 1 receptor |
|
|
ISS |
8 |
115,099,763 |
115,119,362 |
RGD:7207470 |
RGD |
| G |
Snx13 |
sorting nexin 13 |
|
|
ISS |
6 |
53,727,055 |
53,827,207 |
RGD:4140388 |
RGD |
|
|
|
Pathway Gene Annotations |
|
Disease Annotations Associated with Genes in the angiotensin II signaling pathway
|
|
|
|
| Ace | Acute Kidney Injury , Alveolitis, Extrinsic Allergic , Alzheimer Disease , Anuria , Arthritis, Experimental , Asthma , Blepharospasm , Bronchiolitis Obliterans , Carcinoma in Situ , Carcinoma, Pancreatic Ductal , Cardiomyopathy, Alcoholic , Cardiomyopathy, Hypertrophic , Carotid Artery Diseases , Central Nervous System Diseases , Coronary Artery Disease , Coronavirus Infections , Cough , Diabetes Mellitus, Experimental , Diabetes Mellitus, Type 2 , Diabetic Nephropathies , Diabetic Retinopathy , Fibrosis , Gallbladder Neoplasms , Glomerulonephritis , Glomerulonephritis, IGA , Heart Failure , Hypertension , Hypertension, Renovascular , Hypertrophy, Left Ventricular , Insulin Resistance , Intracranial Aneurysm , Kidney Failure, Chronic , Liver Cirrhosis , Liver Cirrhosis, Biliary , Lung Diseases , Lung Neoplasms , Lupus Erythematosus, Systemic , Memory Disorders , MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 3 , Mitral Valve Prolapse , Myocardial Infarction , Obesity , Osteoporosis , Pain , Pancreatic Neoplasms , Parkinson Disease , Pneumonia , Pneumonia, Aspiration , Polycystic Kidney, Autosomal Recessive , Pulmonary Disease, Chronic Obstructive , Pulmonary Fibrosis , RENAL TUBULAR DYSGENESIS , Reperfusion Injury , Respiratory Distress Syndrome, Adult , Sarcoidosis , Scleroderma, Systemic , Sleep Apnea, Obstructive , Stroke | | Agtr1a | AIDS-Associated Nephropathy , Anti-Glomerular Basement Membrane Disease , Aortic Aneurysm, Abdominal , Asthma , Atrial Fibrillation , Carcinoma, Renal Cell , Cardiomegaly , Cardiomyopathy, Dilated , Carotid Artery Diseases , Cerebrovascular Disorders , Coronary Artery Disease , Coronary Disease , Diabetic Nephropathies , Fetal Growth Retardation , Fibrosis , Glomerulonephritis, IGA , Glomerulosclerosis , Glomerulosclerosis, Focal Segmental , Hyperinsulinism , Hypertension , Hypertension, Essential , Hypertension, Pulmonary , Hypertension, Renovascular , Hypertrophy, Left Ventricular , Lung Diseases , Mammary Neoplasms, Experimental , Metabolic Syndrome X , Myocardial Infarction , Myocardial Reperfusion Injury , Nephritis , Placental Insufficiency , Proteinuria , Pulmonary Fibrosis , Radiation Injuries, Experimental , Renal Insufficiency, Chronic , RENAL TUBULAR DYSGENESIS , Sarcoidosis , Vesico-Ureteral Reflux | | Agtr1b | Anuria , Coronary Artery Disease , Hyperaldosteronism , Hypertension , Water-Electrolyte Imbalance | | Agtr2 | AIDS-Associated Nephropathy , Asthma , Carcinoma, Renal Cell , Cardiomyopathy, Dilated , Congenital diaphragmatic hernia , Diabetes Mellitus, Experimental , Diabetes Mellitus, Type 2 , Diabetic Nephropathies , Endotoxemia , Fetal Growth Retardation , Fibrosis , Glomerulonephritis , Glomerulonephritis, IGA , Glomerulosclerosis , Glomerulosclerosis, Focal Segmental , Heart Failure , Hypertension , Hypertension, Renovascular , Hypoglycemia , Hypoxia-Ischemia, Brain , Inflammation , Insulin Resistance , Intellectual Disability , Kidney Failure, Chronic , Lupus Erythematosus, Systemic , Mental Retardation, X-Linked , Obesity , Pancreatic Neoplasms , Pulmonary Fibrosis , Radiation Injuries, Experimental , Renal Insufficiency, Chronic , Reperfusion Injury , Stroke , Urogenital Abnormalities , Vesico-Ureteral Reflux | | Agt | Albuminuria , Alzheimer Disease , Anti-Glomerular Basement Membrane Disease , Breast Neoplasms , Cardiomegaly , Cardiomyopathy, Hypertrophic , Cardiovascular Diseases , Carotid Artery Diseases , Cerebrovascular Disorders , Coronary Artery Disease , Diabetes Mellitus, Type 2 , Diabetic Nephropathies , Fibrosis , Glomerulonephritis, IGA , Glomerulosclerosis, Focal Segmental , Heart Failure , Hepatitis, Alcoholic , Hydronephrosis , Hyperinsulinism , Hypertension , Hypertension, Essential , Hypertension, Pulmonary , Kidney Failure, Chronic , Metabolic Syndrome X , Mitral Valve Prolapse , Myocardial Infarction , Obesity , Pre-Eclampsia , Pulmonary Edema , Renal Insufficiency , RENAL TUBULAR DYSGENESIS , Sciatic Neuropathy , Stroke | | Ccl2 | Acute Lung Injury , Anti-Glomerular Basement Membrane Disease , Aortic Aneurysm, Abdominal , Arteriosclerosis , Arthritis, Experimental , Arthritis, Rheumatoid , Asthma , Bipolar Disorder , Brain Injuries , Brain Ischemia , Bronchial Hyperreactivity , Bronchiolitis Obliterans , Cardiomyopathies , Cardiovascular Diseases , Chagas Disease , Colitis , Colonic Neoplasms , Contusions , Coronary Artery Disease , Cystic Fibrosis , Diabetes Mellitus, Experimental , Diabetes Mellitus, Type 1 , Diabetes Mellitus, Type 2 , Diabetes, Gestational , Diabetic Nephropathies , Encephalomyelitis, Autoimmune, Experimental , Endomyocardial Fibrosis , Endotoxemia , Giant Cell Arteritis , Glomerulonephritis, IGA , Granuloma, Respiratory Tract , Heart Failure , HIV Infections , Hyperalgesia , Hypertension , Hypertension, Pulmonary , Inflammation , Influenza, Human , Insulin Resistance , Intracranial Aneurysm , Kidney Diseases , Kidney Failure, Chronic , Lipodystrophy , Liver Cirrhosis, Experimental , Lung Diseases , Lung Diseases, Interstitial , Macular Edema , MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO , Myocardial Infarction , Neoplasm Metastasis , Neural Tube Defects , Obesity , Pain , Pancreatitis , Pancreatitis, Acute Necrotizing , Periodontitis , Pneumonia , Pneumonia, Bacterial , Pneumonia, Pneumocystis , Pneumonia, Viral , Pulmonary Disease, Chronic Obstructive , Pulmonary Edema , Pulmonary Emphysema , Pulmonary Fibrosis , Reperfusion Injury , Scleroderma, Systemic , Sepsis , Sleep Apnea, Obstructive , Spinal Dysraphism , Status Epilepticus , Stroke , Tuberculosis , Tuberculosis, Pulmonary , Uveitis , Vasospasm, Intracranial , Venous Thrombosis | | Cma1 | Anaphylaxis , Asthma , Cardiomegaly , Cardiomyopathy, Hypertrophic , Dermatitis, Atopic , Diabetes Mellitus, Experimental , Granuloma , Heart Defects, Congenital , Hypertrophy, Left Ventricular , Lung Diseases, Interstitial , Myocarditis , Pulmonary Disease, Chronic Obstructive , Rhinitis, Allergic, Seasonal , Sarcoidosis | | Jak2 | Anemia , Arthritis, Rheumatoid , Brain Injuries , Budd-Chiari Syndrome , Colitis, Ulcerative , Crohn Disease , Encephalomyelitis, Autoimmune, Experimental , Erythrocytosis, Familial, 2 , Fatty Liver , Hyperalgesia , Leukemia, Myeloid, Acute , Lupus Erythematosus, Systemic , Myeloproliferative Disorders , Nephrotic Syndrome , Non-alcoholic Fatty Liver Disease , Obesity , Polycythemia , Polycythemia Vera , Polycythemia, primary familial and congenital , Pregnancy Complications , Primary Myelofibrosis , Reperfusion Injury , Scleroderma, Limited , Scrapie , Spondylitis, Ankylosing , Stroke , Thrombocytosis | |
| Olr1 | Cerebral Amyloid Angiopathy , Coronary Artery Disease , Hypertension , Kidney Failure, Chronic , Myocardial Infarction , Myocardial Reperfusion Injury | |
| Prkcz | Hyperglycemia , Hypertrophy, Left Ventricular , Insulin Resistance | |
| Pancreatic Neoplasms | Ace , Agtr2 | | Osteoporosis | Ace | | Mental Retardation, X-Linked | Agtr2 | | Ischemia | Ccl2 | | Intellectual Disability | Agtr2 | | Inflammation | Agtr2 , Ccl2 | | Fetal Growth Retardation | Agtr1a , Agtr2 | | Heart Defects, Congenital | Cma1 | | Carcinoma, Renal Cell | Agtr1a , Agtr2 | | Renal Insufficiency | Agt | | Blepharospasm | Ace | | Obesity | Agt , Agtr2 , Ace , Ccl2 , Jak2 | | Central Nervous System Diseases | Ace | | Diabetes Mellitus, Type 2 | Agt , Agtr2 , Ace , Ccl2 | | Kidney Diseases | Ccl2 | | Metabolic Syndrome X | Agt , Agtr1a | | Neural Tube Defects | Ccl2 | | Cardiomegaly | Agt , Agtr1a , Cma1 | | Mitral Valve Prolapse | Ace , Agt | | Cardiomyopathies | Ccl2 | | Hypoglycemia | Agtr2 | | Urogenital Abnormalities | Agtr2 | | Cardiomyopathy, Dilated | Agtr1a , Agtr2 | | Lipodystrophy | Ccl2 | | Pulmonary Emphysema | Ccl2 | | Sarcoidosis | Agtr1a , Ace , Cma1 | | Pregnancy Complications | Jak2 | | Hypertension, Pulmonary | Agt , Agtr1a , Ccl2 | | Lung Neoplasms | Ace | | Gallbladder Neoplasms | Ace | | Carcinoma in Situ | Ace | | Colitis | Ccl2 | | Pain | Ace , Ccl2 | | Fatty Liver | Jak2 | | Cardiomyopathy, Hypertrophic | Agt , Ace , Cma1 | | Pneumonia | Ace , Ccl2 | | Nephrotic Syndrome | Jak2 | | Arteriosclerosis | Ccl2 | | Crohn Disease | Jak2 | | Acute Kidney Injury | Ace | | Breast Neoplasms | Agt | | Lung Diseases | Agtr1a , Ace , Ccl2 | | Colitis, Ulcerative | Jak2 | | Polycystic Kidney, Autosomal Recessive | Ace | | Spinal Dysraphism | Ccl2 | | Intracranial Aneurysm | Ace , Ccl2 | | Proteinuria | Agtr1a | | Lupus Erythematosus, Systemic | Agtr2 , Ace , Jak2 | | Kidney Failure, Chronic | Agt , Agtr2 , Ace , Ccl2 , Olr1 | | Hydronephrosis | Agt | | Alzheimer Disease | Ace , Agt | | Arthritis, Rheumatoid | Ccl2 , Jak2 | | Nephritis | Agtr1a | | Diabetes Mellitus, Type 1 | Ccl2 | | Granuloma | Cma1 | | Polycythemia, primary familial and congenital | Jak2 | | Polycythemia | Jak2 | | Alveolitis, Extrinsic Allergic | Ace | | Primary Myelofibrosis | Jak2 | | Uveitis | Ccl2 | | Fibrosis | Agt , Agtr1a , Agtr2 , Ace | | Cystic Fibrosis | Ccl2 | | Hypertension | Agt , Agtr1a , Agtr1b , Agtr2 , Ace , Ccl2 , Olr1 | | Vesico-Ureteral Reflux | Agtr1a , Agtr2 | | Pulmonary Edema | Agt , Ccl2 | | Parkinson Disease | Ace | | Insulin Resistance | Agtr2 , Ace , Ccl2 , Prkcz | | Scleroderma, Systemic | Ace , Ccl2 | | Liver Cirrhosis | Ace | | Glomerulonephritis, IGA | Agt , Agtr1a , Agtr2 , Ace , Ccl2 | | Congenital diaphragmatic hernia | Agtr2 | | Cerebral Amyloid Angiopathy | Olr1 | | Atrial Fibrillation | Agtr1a | | Hyperinsulinism | Agt , Agtr1a | | Glomerulosclerosis, Focal Segmental | Agt , Agtr1a , Agtr2 | | Glomerulonephritis | Ace , Agtr2 | | Giant Cell Arteritis | Ccl2 | | Pre-Eclampsia | Agt | | Liver Cirrhosis, Biliary | Ace | | Non-alcoholic Fatty Liver Disease | Jak2 | | HIV Infections | Ccl2 | | Albuminuria | Agt | | Lung Diseases, Interstitial | Ccl2 , Cma1 | | Memory Disorders | Ace | | Anaphylaxis | Cma1 | | Anemia | Jak2 | | Myeloproliferative Disorders | Jak2 | | Anuria | Ace , Agtr1b | | Arthritis, Experimental | Ace , Ccl2 | | Asthma | Agtr1a , Agtr2 , Cma1 , Ace , Ccl2 | | Hyperaldosteronism | Agtr1b | | Bipolar Disorder | Ccl2 | | Brain Injuries | Ccl2 , Jak2 | | Bronchiolitis Obliterans | Ace , Ccl2 | | Cardiomyopathy, Alcoholic | Ace | | Cardiovascular Diseases | Agt , Ccl2 | | Carotid Artery Diseases | Agt , Ace , Agtr1a | | Cerebrovascular Disorders | Agt , Agtr1a | | Brain Ischemia | Ccl2 | | Chagas Disease | Ccl2 | | Colonic Neoplasms | Ccl2 | | Contusions | Ccl2 | | Coronary Disease | Agtr1a | | Coronary Artery Disease | Agt , Agtr1a , Agtr1b , Ace , Ccl2 , Olr1 | | Cough | Ace | | Water-Electrolyte Imbalance | Agtr1b | | Dermatitis, Atopic | Cma1 | | Diabetes Mellitus, Experimental | Agtr2 , Ace , Ccl2 , Cma1 | | Diabetic Nephropathies | Agt , Agtr1a , Agtr2 , Ace , Ccl2 | | Diabetic Retinopathy | Ace | | Heart Failure | Agt , Agtr2 , Ace , Ccl2 | | Encephalomyelitis, Autoimmune, Experimental | Ccl2 , Jak2 | | Endomyocardial Fibrosis | Ccl2 | | Coronavirus Infections | Ace | | Leukemia, Myeloid, Acute | Jak2 | | Diabetes, Gestational | Ccl2 | | Granuloma, Respiratory Tract | Ccl2 | | Rhinitis, Allergic, Seasonal | Cma1 | | Budd-Chiari Syndrome | Jak2 | | Venous Thrombosis | Ccl2 | | Hepatitis, Alcoholic | Agt | | Hyperalgesia | Ccl2 , Jak2 | | Hyperglycemia | Prkcz | | Hypertension, Renovascular | Agtr1a , Agtr2 , Ace | | Influenza, Human | Ccl2 | | Renal Insufficiency, Chronic | Agtr1a , Agtr2 | | Liver Cirrhosis, Experimental | Ccl2 | | Neoplasm Metastasis | Ccl2 | | Macular Edema | Ccl2 | | Mammary Neoplasms, Experimental | Agtr1a | | Myocardial Infarction | Agt , Agtr1a , Ace , Ccl2 , Olr1 | | Myocarditis | Cma1 | | Pancreatitis | Ccl2 | | Periodontitis | Ccl2 | | Sleep Apnea, Obstructive | Ace , Ccl2 | | Placental Insufficiency | Agtr1a | | Pneumonia, Aspiration | Ace | | Pneumonia, Bacterial | Ccl2 | | Pneumonia, Pneumocystis | Ccl2 | | Pneumonia, Viral | Ccl2 | | Polycythemia Vera | Jak2 | | Pulmonary Fibrosis | Agtr1a , Agtr2 , Ace , Ccl2 | | Radiation Injuries, Experimental | Agtr1a , Agtr2 | | Respiratory Distress Syndrome, Adult | Ace | | Sciatic Neuropathy | Agt | | Scrapie | Jak2 | | Sepsis | Ccl2 | | Tuberculosis, Pulmonary | Ccl2 | | Spondylitis, Ankylosing | Jak2 | | Status Epilepticus | Ccl2 | | Thrombocytosis | Jak2 | | Tuberculosis | Ccl2 | | Reperfusion Injury | Agtr2 , Ace , Ccl2 , Jak2 | | Myocardial Reperfusion Injury | Agtr1a , Olr1 | | AIDS-Associated Nephropathy | Agtr1a , Agtr2 | | Bronchial Hyperreactivity | Ccl2 | | Hypertrophy, Left Ventricular | Agtr1a , Cma1 , Ace , Prkcz | | Aortic Aneurysm, Abdominal | Agtr1a , Ccl2 | | Scleroderma, Limited | Jak2 | | Pancreatitis, Acute Necrotizing | Ccl2 | | Endotoxemia | Agtr2 , Ccl2 | | Anti-Glomerular Basement Membrane Disease | Agt , Agtr1a , Ccl2 | | Vasospasm, Intracranial | Ccl2 | | Stroke | Agt , Agtr2 , Ace , Ccl2 , Jak2 | | Hypoxia-Ischemia, Brain | Agtr2 | | Carcinoma, Pancreatic Ductal | Ace | | Pulmonary Disease, Chronic Obstructive | Ace , Ccl2 , Cma1 | | Acute Lung Injury | Ccl2 | | RENAL TUBULAR DYSGENESIS | Agt , Ace , Agtr1a | | MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 3 | Ace | | MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO | Ccl2 | | Hypertension, Essential | Agt , Agtr1a | | Erythrocytosis, Familial, 2 | Jak2 | | Glomerulosclerosis | Agtr1a , Agtr2 | |
|